hhg logo
hygeia logo
hospital logo
mitera logo
general logo
lito logo
creta interclinic logo
Απολλώνειο logo
health spot
Hygeia IVF - Εμβρυογένεσις
alab
digital clinic
Heal Academy
business care
business care
logimed
Θεραπευτήριο Metropolitan Θεραπευτήριο Metropolitan
  • Ελληνικά
  • English
  • Home
  • About Us
    • About Metropolitan General
    • Testimonials
    • Our Vision & Mission
    • Scientific Committee
    • Quality & Safety
      • Certifications & Distinctions
      • Quality Policy
      • Complaints Submission Process
    • Human Resources
      • Training
      • Benefits
      • Career Opportunities
    • State of the art technology
    • Corporate Social Responsibility
  • Medical Services
    • General Services
      • Anesthesiology
      • Breast Center
      • Cardiac Surgery
      • Cardiology
      • Nutrition & Clinical Dietetics
      • Dermatology
      • Diabetes Center
      • E.N.T.
      • Endocrinology
      • Gastroenterology
      • General Surgery
      • Hematology
      • Hepatology
      • Internal Medicine
      • Interventional Cardiology
      • Advanced Interventional Endoscopy
      • Interventional Neuroradiology
      • Interventional Radiology
      • Medical Physics
      • Nephrology
      • Neurology
      • Neurosurgery
      • Oncology
      • Ophthalmology
      • Oral & Maxillofacial Surgery
      • Orthopedics
      • Physiotherapy
      • Plastic & Reconstructive Surgery
      • Pulmonology
      • Rheumatology
      • Robotic Surgery (Da Vinci)
      • Robotic Urology (Da Vinci)
      • Thoracic Surgery
      • Urology
      • Vascular Surgery
    • Innovative Services
    • Specialized Units
      • Αcute Stroke Unit (ASU)
      • Hemodialysis Unit
      • Lithotripsy Unit
      • One Day Clinic (O.D.C)
      • Pathological Oncology Unit
      • Polyvalent Intensive Care Unit
    • Clinics & Special Departments
    • Laboratories
      • Anatomical Pathology
      • Bone Density Measurement
      • Breast Imaging
      • Bronchoscopic laboratory
      • Cardiac Catheterization Laboratory
      • Cardiology
      • Central Laboratories
      • CT-scan
      • Endoscopy Laboratory
      • Ιn - lab Sleep Study
      • X-Ray Laboratory
      • Neurophysiology Laboratory
      • Nuclear Medicine
      • ΜRI-Scan
      • Pulmonary Function Lab
      • Ultrasounds
      • Orthopantomogram
    • Outpatient Department
    • Check Up
      • Check Up BASIC
      • Check Up PLUS
      • Check Up Just For U Women
      • Check Up Just For U Men
      • Check Up Just For U Heart
      • Check Up Just For U Osteoporosis
      • Check Up Just For U Lipidemic Profil
      • Check Up Just For U Thyroid
      • Check Up Just For U Rheumatology
      • Check Up Just For U Diabetes
    • Emergency Department
    • Nursing
    • Αmbulances
    • Medical Tourism
    • Price List
  • Doctors
  • Information
    • Patients
      • Admission
      • Hospitalization
      • Discharge Procedure
      • Medical Records Office
    • Visitors
    • General Instructions for Patients and Escorts
    • Access
    • Valet Parking
    • Insurance Companies
    • Social security funds
  • Media
    • Photos
    • Leaflets
  • Contact Us

Temos

 

  • CLINIC OF ONCOLOGIC
    CLINICAL STUDIES AND RESEARCH
  • CLINIC OF ONCOLOGIC
    CLINICAL STUDIES AND RESEARCH
  • Νοσοκομείο
  • Services
  • Clinics & Special Departments
  • Clinic of Oncologic Clinical Studies and Research

ONCOLOGY CLINICAL TRIALS AND RESEARCH CLINIC

The Clinic of Oncology Clinical Trials and Research covers all standard and novel, approved, groundbreaking, targeted, and personalized treatments in the field of Oncology. Through partnerships with the Departments at Metropolitan General, other Group Hospitals, Academic Institutions/Departments, and Oncology Centers, our Clinic offers modern, robust, and diverse approaches for the investigation, diagnosis, management, and treatment of oncology patients.

The Clinic of Oncology Clinical Trials and Research was developed to address the needs of oncology patients and their family environment, based on an axis of 4 pillars.

  1. Provision of disease-specific, patient-applicable, scientifically established, and worldwide acknowledged diagnostic and treatment modalities.
  2. Opportunity to take part in highly regarded international Oncology Clinical Trials
  3. Early access to treatments with demonstrated effectiveness that are not currently marketed in our country, through no-cost early access programs.
  4. Participation in research studies, such as the development/identification of biomarkers for suitable and efficient treatment selection

INTERNATIONAL CLINICAL TRIALS

The Clinic of Oncology Clinical Trials and Research participates in a considerable number of clinical trials in patients with metastatic prostate cancer, metastatic colon/rectal cancer, metastatic kidney cancer, bladder cancer/urothelial cancer, small cell lung cancer, and other tumor diseases.

The Clinical Trials team consists of the following members:

Principal Investigator:

Evangelos Bournakis, Medical Oncologist

Chief of Oncology Clinical Trials and Research Clinic

Sub-investigators:

Nikolaos Soupos, Medical Oncologist

Nikolaos Skandalakis, Cardiologist

Eleni Zerva, Physician

Study Coordinator:

Athanasios Bournakis MSc, Chemical Engineer

Study Nurses:

Stamatia Kotsia, Head of One Day Clinic at Metropolitan General

WHAT IS A CLINICAL TRIAL?

A clinical trial is a procedure to confirm a drug’s already established safety and efficacy. A study drug is compared either to a placebo (pharmacologically inactive substance), when there is no standard treatment, or to current standard treatments to determine whether it is more effective and help approve its market release and administration in daily clinical practice.

In settings where there is already a standard treatment with a proven survival benefit, a study drug is compared combined with the standard treatment versus standard treatment alone, to determine whether adding this new drug to the standard treatment would result to a greater survival benefit or disease response compared to that standard treatment alone.

HOW CAN A PATIENT BENEFIT FROM TAKING PART IN A CLINICAL TRIAL?

Being involved in clinical research offers multiple benefits, including receiving a high standard of therapeutic approach and monitoring according to a strict, internationally established framework that governs the clinical protocol of each study.

Through participation in clinical trials, the following are achieved:

  1. Access to modern treatments that combine an internationally approved treatment with the addition of a new study intervention at no cost to the patient or their payer.

All study patients have free of charge access to our Hospital’s services to undergo study-related tests and procedures (blood testing, imaging Trials, biopsies, One Day Clinic for the administration of the study drug, inpatient stay, medical and tumor follow-up by the study physicians).

Depending on the requirements of the clinical research, patients often have the possibility to undergo modern imaging, laboratory, or genetic testing at no cost; such tests are particularly expensive and, occasionally, not covered by payers.

Additionally, patient transportation costs to and from the Hospital and their accommodation are usually covered in many international clinical trials. This makes it easier for patients from all around Greece to access high-level treatment options during these challenging economic times.

  1. The opportunity to access advanced and promising treatments earlier than they are marketed worldwide, provided that research demonstrates such treatments to have a therapeutic benefit in cure or overall survival improvement.

This is a particularly important fact, especially for people with incurable, usually metastatic, malignancies.

  1. The opportunity to receive treatments when standard treatment options are limited or exhausted.
  2. The opportunity for uninsured people to receive the best standard treatment combined with the study intervention, in a prestigious hospital setting, at no cost.

NOTE: Participation in a clinical study is ONLY offered if this is actually the best possible disease-specific treatment option and ONLY after the prospective participant has received full and detailed information on the study. Participation in a clinical study IS VOLUNTARY. Participation in a clinical study is not binding, even if a participant has initially agreed and signed the Patient Consent Form. Participants may withdraw from the study at their discretion and/or the study physician’s discretion.

In international clinical trials, protocol-related supply of drugs and paraclinical tests are free of charge both for patients and their payer.

EARLY ACCESS PROGRAMS

Early access programs refer to new drug therapies that have demonstrated their efficacy in treating target malignancies, have been approved by the US FDA (United States Food and Drug Administration) and/or by the EMA (European Medicines Agency), however, they are not currently on the Greek market, typically for pricing reasons.

Through such programs, one can have access to these interventions, much earlier than these are priced and prescribed. Thus, study drugs can offer their benefit sooner to people who need them at no cost (in some programs, even payers are not financially burdened, as the drug is provided free of charge by the pharmaceutical company that manufactures it - in this case, a program enrolls only a limited number of patients)

Early access programs are not clinical trials.

There is currently no open early access program in our Clinic.

  • Early access program in non-metastatic castration-resistant prostate cancer. Free of charge delivery of/access to apalutamide in non-metastatic castration-resistant prostate cancer
    (closed program; drug already covered by EOPYY [Greek National Organization for the Provision of Health Services])
  • Early access program in extensive stage small cell lung cancer, first-line treatment. Free of charge delivery of/access to standard etoposide-platinum chemotherapy
    (closed program; drug already covered by EOPYY [Greek National Organization for the Provision of Health Services])

RESEARCH PROGRAMS

  • Prognostic and predictive value of tumor molecular alterations in patients with prostate cancer TR_9/2

  closed program

HOW CAN I FIND OUT IF I AM ELIGIBLE FOR A CLINICAL TRIAL, EARLY ACCESS PROGRAM, OR RESEARCH PROGRAM?

You can search on the websites of Metropolitan General Hospital and Oncology Clinical Trials and Research Clinic for Clinical Trials, Early Access Programs, and Research Programs that are currently open or anticipated to open. Then, you can get in touch with the Clinic's Oncologists to schedule an appointment and find out whether you might be able to participate in one of them, depending on the nature of your medical condition.*

If you already under medical care, your attending physician can also inform you about the value of clinical trials and discuss your participation in one of them with you or refer you to someone from our Oncology Clinical Trials and Research Clinic Team.

*For everyone's safety during these hard times and to prevent the spread of COVID-19, you can also send any inquiries or questions you may have about our Clinic’s ongoing Clinical Trials, Early Access Programs, or Research Programs to the e-mail below: OncoCTR.Clinic@yahoo.com

GASTROINTESTINAL CANCER – STOMACH/DUODENAL, PANCREAS/BILE DUCTS, COLORECTUM (GI CANCERS)

  • KRYSTAL-10 study, Protocol 849-010

A phase 3, randomized study of MTRX849 in combination with cetuximab versus chemotherapy in patients with advanced colorectal cancer with a G12C mutation in the KRAS gene with disease progression during or after standard first-line treatment – open study, open patient enrollment

  • CA209-8HW study

A phase 3b, randomized study of nivolumab monotherapy versus nivolumab plus ipilimumab, or investigator's choice chemotherapy, in patients with metastatic colorectal cancer and microsatellite instability (MSI-H) or mismatch repair deficient (dMMR) (for patients either in first-line treatment or in any line of treatment-treatment experienced) – open study, open patient enrollment

  • ISO-CC-007 study (AGENT STUDY)

A phase 3, randomized, multicenter, parallel-group study comparing the efficacy of arfolitixorin versus leucovorin combined with 5-fluorouracil, oxaliplatin, and bevacizumab in patients with advanced colorectal cancer (first-line treatment) – closed study

GENITOURINARY CANCER – PROSTATE, KIDNEY, UROTHELIUM (GU CANCERS)

  • CAPItello 280 study (prostate cancer)

A phase 3, double-blind, randomized, placebo-controlled study evaluating the efficacy and safety of capivasertib + docetaxel versus placebo + docetaxel as treatment in patients with metastatic castration-resistant prostate cancer (mCRPC) – open study, open patient enrollment

  • CONTACT-02_XL184-315 study (prostate cancer)

A phase 3, randomized study of cabozantinib combined with atezolizumab versus the second newer hormonal agent (enzalutamide or abiraterone) in patients with high-risk, metastatic castration-resistant prostate cancer – open study, open patient enrollment

  • CA017-078 study (bladder/urothelial cancer)

A phase 3, randomized study of induction chemotherapy alone versus induction chemotherapy plus nivolumab or nivolumab and BMS-986205, followed by continued postoperative treatment with nivolumab or nivolumab and BMS-986205 in patients with muscle invasive bladder cancer – closed for patient enrollment

  • CPZ034AGR06 - ATLAS non-interventional study (kidney cancer)

A phase 4, prospective, observational study in patients with advanced renal cell carcinoma to evaluate the efficacy and duration of responses to pazopanib as first-line treatment – closed study

  • CO39303 study (prostate cancer)

A phase 3, randomized, double-blind, placebo-controlled, multicenter study of ipatasertib plus abiraterone plus prednisone/prednisolone versus placebo plus abiraterone plus prednisone/prednisolone in previously untreated patients with asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer (November 2017- ) – closed for patient enrollment

  • Phase 3 PRESIDE study (prostate cancer)

A study to evaluate the benefit of enzalutamide treatment after disease progression in men initiated on docetaxel treatment after progression of their metastatic castration-resistant prostate cancer while on enzalutamide alone (September 2015- ) – closed for patient enrollment

  • CO39385 study (prostate cancer)

A phase 3, multicenter, randomized, placebo-controlled, double-blind study of atezolizumab combined with enzalutamide versus enzalutamide alone in patients with metastatic castration-resistant prostate cancer after treatment failure with androgen biosynthesis inhibitor and treatment failure or failure to adhere or treatment refusal of the taxane-based chemotherapeutic regimen (October 2017- ) – closed for patient enrollment

LUNG CANCER

  • GO41767 - SKYSCRAPER Study (small cell lung cancer)

A phase 3, randomized, double-blind, placebo-controlled study to compare treatment with atezolizumab and carboplatin and etoposide with or without tiragolumab (anti-TIGIT antibody) in previously untreated patients with extensive stage small cell lung cancer (September 2020- ) – closed for patient enrollment

GYNECOLOGICAL CANCER – OVARIES, UTERUS/ENDOMETRIUM, CERVIX (GY CANCERS)

BREAST CANCER

MICROCYTIC LUNG CANCER

MICROCYTIC LUNG CANCER

Clinical Study GO41767

This is a Phase 3, randomized, double-blind, placebo-controlled comparison study of a therapy with atezolizumab and carboplatin and etoposide with or without tiragolumab (anti-TIGIT antibody) to patients with extensive-stage microcytic lung cancer who have never received any other treatment. (This study is active and patient induction continues)

 

Staff

Principal Investigator
Evangelos Bournakis, Pathologist Oncologist, Director of the Oncology Medical Study and Investigation Clinic

Sub-Investigators
Nikolaos Soupos, Pathologist-Oncologist
Nikolaos Skandalakis, Cardiologist
Eleni Zerva,Physician

Study Coordinator
Athanasios Bournakis MSc, Chemical Engineer

Study Nurse
Stamatia Kotsia, Director of the Brief Hospitalization Department at Metropolitan General

 

 

  • Share
  • Tweet
  • Share
  • Share
General Services
Anesthesiology
Breast Center
Cardiac Surgery
Cardiology
Nutrition & Clinical Dietetics
Dermatology
Diabetes Center
E.N.T.
Endocrinology
Gastroenterology
General Surgery
Hematology
Hepatology
Internal Medicine
Interventional Cardiology
Advanced Interventional Endoscopy
Interventional Neuroradiology
Interventional Radiology
Medical Physics
Nephrology
Neurology
Neurosurgery
Oncology
Ophthalmology
Oral & Maxillofacial Surgery
Orthopedics
Physiotherapy
Plastic & Reconstructive Surgery
Pulmonology
Rheumatology
Robotic Surgery (Da Vinci)
Robotic Urology (Da Vinci)
Thoracic Surgery
Urology
Vascular Surgery
Innovative Services
Heart MRI
Robotic Gynecology
DEPARTMENT OF PALLIATIVE CARE
Specialized Units
Αcute Stroke Unit (ASU)
Hemodialysis Unit
Lithotripsy Unit
One Day Clinic (O.D.C)
Pathological Oncology Unit
Polyvalent Intensive Care Unit
Clinics & Special Departments
Laboratories
Anatomical Pathology
Bone Density Measurement
Breast Imaging
Bronchoscopic laboratory
Cardiac Catheterization Laboratory
Cardiology
Central Laboratories
CT-scan
Endoscopy Laboratory
Ιn - lab Sleep Study
X-Ray Laboratory
Neurophysiology Laboratory
Nuclear Medicine
ΜRI-Scan
Pulmonary Function Lab
Ultrasounds
Orthopantomogram
Outpatient Department
Check Up
Check Up BASIC
Check Up PLUS
Check Up Just For U Women
Check Up Just For U Men
Check Up Just For U Heart
Check Up Just For U Osteoporosis
Check Up Just For U Lipidemic Profil
Check Up Just For U Thyroid
Check Up Just For U Rheumatology
Check Up Just For U Diabetes
Emergency Department
Nursing
Αmbulances
Medical Tourism
Price List

SEE ALSO

PrevNext
AMBULANCES
Approved by the Greek National Center of Emergency Care (EKAV), Metropolitan General’s ultramodern ambulances are...
AMBULANCES
CHECK UP
Placing great emphasis on prevention, Metropolitan General accommodates a well equipped and fully organized Check-up...
CHECK UP
INNOVATIVE SERVICES
INNOVATIVE SERVICE...
ABOUT METROPOLITAN GENERAL
Metropolitan General is a member of Ηellenic HealthCare Group, the largest private health care group in...
ABOUT METROPOLITAN...
MEDICAL TOURISM
  Metropolitan General accommodates a special International Patient Department aiming to the best possible service and...
MEDICAL TOURISM
OUR VISION & MISSION
Today, Metropolitan General is a pioneer hospital that does not consider the provision of high-quality...
OUR VISION & MISSI...
EMERGENCY DEPARTMENT
The Emergency Department at Metropolitan General operates on a 24-hour basis and immediately and effectively...
EMERGENCY DEPARTME...
OUTPATIENT DEPARTMENT
Responsible and comprehensive treatment-care of all medical cases (internal medicine, surgery, cardiology, orthopedics, etc.) staffed...
OUTPATIENT DEPARTM...
QUALITY POLICY
The Management of Metropolitan General, acknowledging that proper medical diagnosis, healthcare and treatment of patients...
QUALITY POLICY

Νοσοκομείο Metropolitan

Book your appointment online quickly and easily!

REQUEST AN APPOINTMENTPRICE LIST

GIVING IT

ALL FOR

YOUR HEALTH

ΣΥΝΔΕΣΗ/ΑΠΟΣΥΝΔΕΣΗ

© 2023 Metropolitan General
Web Design by CnC Tech & Ruler

ADDRESS

264 Mesogion Avenue

GR-15562 Holargos

EMERGENCY (24/7)

CALL CENTER 210 6502000

AMBULANCE 210 6502627

APPOINTMENT

infogeneral@metropolitan-hospital.gr

TELEPHONE 210 6502000

CERTIFICATIONS

      preferred partner 2020Quality in International Care  ISO 9001  iso9001 s COEHS

OFFICIAL SPONSOR

AEK BC logoOlympic Winners logo